Why eosinophilia occurs in malignancy
Reading File
Finding Sources
Finding Sources
Searching PubMed
eosinophilia malignancy mechanism
Reading File
Reading File
Finding Sources
Reading File
I now have comprehensive information from two authoritative textbooks. Here is the full answer:
Eosinophilia in Malignancy
Eosinophilia occurs in approximately 1% of all cancer patients. The mechanisms differ depending on whether the eosinophilia is reactive (paraneoplastic) or clonal (part of the neoplastic process itself).
1. Reactive / Paraneoplastic Eosinophilia
This is the most common mechanism. Tumor cells or associated immune cells produce cytokines that drive eosinophil production in the bone marrow:
Key cytokine: IL-5
- Tumors and tumor cell lines - especially from lymphomas and leukemias - produce IL-5, the primary growth and survival factor for eosinophils.
- IL-5 directly stimulates eosinophil proliferation, differentiation, and prolonged survival.
- The genes for IL-5 and related cytokines are clustered on the long arm of chromosome 5 (5q). Chromosomal translocations involving 5q (seen in some lymphomas/leukemias) can activate IL-5 transcription, leading to eosinophil overproduction.
Other contributors:
- IL-3 and GM-CSF are also produced by some tumors and contribute to eosinophilopoiesis.
- The chemokine eotaxin works alongside IL-5 to influence eosinophil migration from bone marrow to peripheral blood and tissues.
(Harrison's Principles of Internal Medicine 22E, p. 543)
2. Clonal Eosinophilia
In some hematologic malignancies, the eosinophils themselves are part of the neoplastic clone - not a reaction to the tumor:
| Malignancy | Mechanism |
|---|---|
| B lymphoblastic leukemia with t(5;14)(q31;q32) | Translocation fuses the IL3 gene (chromosome 5) to the IgH locus (chromosome 14), causing constitutive IL-3 overexpression and eosinophilia as a clonal feature |
| Chronic eosinophilic leukemia / myeloproliferative neoplasms | Clonal expansion of eosinophil precursors due to mutations (e.g., PDGFRA/PDGFRB fusions) |
| Lymphocytic variant HES | Abnormal T-cell clone secretes IL-5 continuously |
(Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 728-729)
3. Associated Malignancies
| Malignancy | Approximate Frequency |
|---|---|
| Hodgkin lymphoma | ~10% of cases |
| Peripheral T-cell lymphomas | Common (paraneoplastic) |
| Lung cancer | ~3% |
| Cervical, GI, renal, breast cancers | Occasional |
Paraneoplastic eosinophilia in Hodgkin lymphoma is a classic board-tested association - Reed-Sternberg cells and surrounding reactive T-cells produce IL-5 directly.
4. Clinical Consequences
- Most patients are asymptomatic.
- When eosinophil counts exceed 5000/μL, patients can develop:
- Shortness of breath and wheezing
- Diffuse pulmonary infiltrates (from eosinophil infiltration and activation in the lungs)
- Potential end-organ damage (cardiac, neurologic) if prolonged - similar to hypereosinophilic syndrome
5. Treatment
- Definitive treatment targets the underlying malignancy (resection, radiation, chemotherapy). Eosinophilia typically resolves with tumor control.
- For symptomatic respiratory involvement, oral or inhaled glucocorticoids provide relief.
- IL-5 antagonists (e.g., mepolizumab) exist but have not been formally evaluated in malignancy-associated eosinophilia.
(Harrison's Principles of Internal Medicine 22E, p. 553)
Summary of mechanisms:
Tumor/malignant cells secrete IL-5 (+ IL-3, GM-CSF) → bone marrow stimulation → eosinophil overproduction → peripheral eosinophilia. In some hematologic malignancies (e.g., t(5;14) B-ALL), eosinophilia is clonal, not reactive. Chromosome 5q rearrangements are the molecular link tying IL-5 gene dysregulation to both paraneoplastic and clonal forms.
This is a shared conversation. Sign in to Orris to start your own chat.